Of potential importance for both IPF and COPD is the capacity of CPA3 to regulate smooth muscle constriction, blood vessel tonus, and vascular flow through proteolytic modification of, e.g., endothelin-1, angiotensin I, apolipoprotein B, and neurotensin (46, 47). Here, CPA3 is linked to chronic obstructive pulmonary disease.